NCT05915013View on ClinicalTrials.gov

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Depressive Disorder, MajorPost Traumatic Stress Disorder
Interventions
DRUG

Ketamine

Intravenous ketamine

DRUG

Perampanel

Oral perampanel (6 mg)

DRUG

Placebo

Oral placebo

Trial Locations (1)

06511

RECRUITING

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER